Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB-CART2019.1 versus standard of care in transplant-ineligible relapsed/refractory DLBCL
2020-003908-14Phase 2Active
- Sponsor
- Miltenyi Biomedicine GmbH
- Start
- Jan 2021
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in diffuse large B-cell lymphoma (DLBCL) and mature B-cell lymphoma comparing MB-CART2019.1 with Standard of care (2 arms). Primary endpoint: Event-free survival. Started Jan 2021; status: active.
02
Drugs
zamtocabtagene autoleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mature B-cell lymphoma
Beyond the preview
Go deeper on 2020-003908-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003908-14.